An observational study in Neurologically Unimpaired Elderly Participants, Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI), sponsored by Casa di Cura IGEA. Recruiting at 1 site in Italy. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-13.
Sponsored by Casa di Cura IGEA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 175 studies in Cognitive Dysfunction with a site in Italy — 74 open to participants now, 87 under way, 6 of them phase 3. Cognitive Dysfunction · Italy.
Among the 175 studies in Cognitive Dysfunction with a site in Italy, this one is the 16th largest by planned enrollment of the 64 observational ones that give a count, is one of 30 that started in 2024, is one of 64 observational ones, reaches primary completion later than 41 of the 86 other live ones, and was the 116th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →74 of the 175 studies in Cognitive Dysfunction with a site in Italy are open now. Recruiting first, the newest first:
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 18–85 · Healthy volunteers
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18+
Alfonso Magliacano · Sites in Italy
Ages 18–75 · Healthy volunteers
University of Milano Bicocca · Sites in Italy
Ages 65+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 55–80 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
175 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 8 · Phase 4 1
First in 2007; this study’s year is marked. 30 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 390 is above the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 80 across the 111 interventional studies, 182 across the 64 observational. Of the 59 that completed or were terminated, 7 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 175 have an industry lead sponsor. The 10 most frequent:
Casa di Cura IGEA is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Casa di Cura IGEA has 2 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
23 of the studies in Cognitive Dysfunction with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06657274IRCCS Centro San Giovanni di Dio FatebenefratelliEARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069 | 2026-11-30 |
| NCT07286448Giovanna ZamboniPersonalized Digital Training for COGnitive FITness in Mild Cognitive Impairment | 2026-11-30 |
| NCT06701630Casa di Cura IGEAItalian Adaptation and Validation of Functional and Behavioural Scales for Subjective Cognitive Decline, Mild Cognitive Impairment and Mild Dementia. | 2026-11-30 |
| NCT07616050Marta MondelliniEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 175 studies in Cognitive Dysfunction with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The first aim of the observational study is the translation, cross-cultural adaptation and validation of functional and behavioral scales used in the diagnosis of neurodegenerative diseases, for which a formal version in Italian is not available at present. In particular, the study includes the following functional and behavioral scales: the Katz's index (Basic Activities of Daily Living, BADL), the Lawton and Brody's scale (Instrumental Activities of Daily Living, IADL), the Everyday Cognition questionnaire (E-Cog), the Neuropsychiatric Inventory Questionnaire (NPI-Q) for assessing the Behavioral and Psychological Symptoms of Dementia. Furthermore, a modified Italian version of the Functional Activities Questionnaire (FAQ), which integrates and updates the content of the original items (e.g., addressing the use of technologies, M-FAQ) will be used in the validation study.
The second aim is to evaluate the psychometric properties of the M-FAQ, the ECog, and the NPI-Q in terms of reliability and validity.
The third aim is to apply a Receiver Operating Characteristic (ROC) curve analysis to identify cut-offs of IADL, M-FAQ and ECOG to discriminate between different clinical groups (i.e., neurologically unimpaired elderly; Subjective Cognitive Decline, SCD; Mild Cognitive Impairment, MCI; mild Alzheimer's Disease, AD).
Neurologically unimpaired elderly participants (over 60 years old) and participants with SCD, MCI, mild AD, and their caregivers/informants will undergo: i) administration of the translated versions of the scales; ii) administration of a Cognitive Reserve questionnaire. For SCD, MCI and AD participants, data from the clinical neuropsychological evaluation will also be collected, while paper-and-pencil psychometric tests to assess global cognitive functioning (Mini Mental State Examination) and logical-abstract reasoning (Raven's Colored Matrices) will be administered to the neurologically unimpaired participants.
Background Increasing aging in high-income countries, linked to increased life expectancy and declining birth rates, is accompanied by an exponential increase of dementia.
While the use of psychometric cognitive tests validated in different clinical populations is commonly used in clinical practice, there is a relative lack of validated Italian-language tools to assess functional autonomy abilities and detect the presence of neuropsychiatric symptoms, even though these are essential aspects for diagnostic, prognostic, and preventive purposes.
The assessment of functional indepedence is particularly important in the diagnosis of Mild Cognitive Impairment (MCI), where the presence of substantially intact or minimally impaired functional abilities is not easy to operationalize and measure, although it has significant relevance especially in the differential diagnosis with overt mild dementia. Currently, the functional scales most used in clinical settings are the Basic Activities of Daily Living scale (BADL), the Instrumental Activities of Daily Living scale (IADL) and the Functional Activities Questionnaire (FAQ). However, the Italian versions of these tools are informal. The group of Farias and colleagues (2008) has more recently developed a new assessment tool, the Everyday Cognition questionnaire (ECog), with a focus on functional changes in specific cognitive domains (memory, language, visuospatial skills, and executive functions).
The Neuropsychiatric Inventory (NPI) is one of the most widely used tools for assessing the Behavioral and Psychological Symptoms of Dementia (BPSD) in research, covering a wide range of neuropsychiatric symptoms. In 2000, a questionnaire form was published, the Neuropsychiatric Inventory Questionnaire (NPI-Q), which is more suitable for use in routine clinical practice and has been validated in several countries, but not in Italian.
Study design According to a power analysis, 300 neurologically unimpaired elderly participants and 90 participants, divided into Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI) and mild Alzheimer's Disease (AD), will participate in the study.
Inclusion criteria:
For all groups: i) Age ≥ 60 years; ii) Availability of an informant/caregiver, able to judge their functional abilities.
For neurologically unimpaired elderly: i) Normal performance on the Mini Mental State Examination.
For clinical groups: conditions consistent with:
Methods Participants and their caregivers/informants will undergo: i) Detailed information of the purpose and modalities of the study, verification of eligibility criteria, signing of informed consent; ii) Collection of demographic and anamnestic data; iii) Administration of the translated versions of the functional rating scales and NPI-q; iiii) Administration of a Cognitive Reserve questionnaire (e.g., Cognitive Reserve Index questionnaire).
For SCD, MCI and AD participants, data from the neuropsychological evaluation clinically performed will also be collected.
Two paper-and-pencil psychometric tests will be administered to neurologically unimpaired participants, to assess global cognitive functioning (Mini Mental State Examination) and logical-abstract reasoning (Raven's Colored Matrices).
Each functional scale will be administered both in the self-report version, in which the participant will provide responses relative to his or her own functioning, and in the informant version, in which the informant or caregiver will be asked to give a rating to his or her relative or friend's functioning in daily activities. The NPI-Q will be administered only to the informant.
Socio-demographic information (age, gender, manual laterality, education, and cognitive reserve assessed through specific questionnaires, e.g., CRI-Q) will be collected from all participants.
A pilot version of each translated scale will be administered, as a semi-structured interview, to about 20 participants and their informants, in order to obtain a final version for each tool to be used in the validation study.
Statistical analysis The distribution of the responses provided by the four clinical groups to the different items of the functional scales (ADL, IADL, M-FAQ and ECog) and the NPI-Q questionnaire will be analyzed to detect the presence of any ceiling and floor effects. The degree of agreement between the self-administered version and the informant version in each tool will be assessed. Cronbach's Alpha coefficient will be employed to analyze the internal consistency of ECOG, M-FAQ and NPI-Q. Convergent validity between functional scales will be calculated.
A confirmatory factor analysis will be employed to examine the factorial structure of the ECog compared to the original version.
Discriminant validity will be assessed by comparing M-FAQ and ECOG by the four scores in different clinical groups through logistic regression models.
Finally, a Receiver Operating Characteristic (ROC) curve analysis will finally be applied to identify cut-offs of IADL, M-FAQ, and ECOG to discriminate among the different clinical groups.
Expected results Italian versions of functional and behavioral scales will be obtained, according to a rigorous cross-cultural adaptation procedure, and overcoming divergences between the available Italian informal versions.
The study will also make available a modified version of the Functional Activities Questionnaire (M-FAQ) that integrates and updates the original items.
Pre-clinical and clinical validation of the tools included in the study will improve early diagnosis and longitudinal monitoring overtime.
The study will enroll neurologically unimpaired participants and participants with SCD, MCI, and mild dementia referred to the Center for Cognitive Disorders and Dementia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For neurologically unimpaired elderly:
For clinical groups: Conditions consistent with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
i) Age ≥ 60 years; ii) Availability of an informant/caregiver, able to judge their functional abilities; iii) Normal performance on the Mini Mental State Examination (Folstein et al. 1975; Foderaro et al., 2022).
i) Age ≥ 60 years; ii) Availability of an informant/caregiver, able to judge their functional abilities. iii) Conditions consistent with Subjective Cognitive Decline according to Jessen et al. (2014)
i) Age ≥ 60 years; ii) Availability of an informant/caregiver, able to judge their functional abilities. iii) Conditions consistent with Mild Cognitive Impairment according to Winblad et al. (2004)
i) Age ≥ 60 years; ii) Availability of an informant/caregiver, able to judge their functional abilities iii) Conditions consistent with a Mild Major Neurocognitive Disorder according to DSM-5-TR (APA, 2022).
Everyday Cognition questionnaire score
The tool assesses functional changes in specific cognitive domains (memory, language, visuospatial skills, and executive functions).
Time frame: From enrollment to the end of the assessment (1 day)
Basic Activities of Daily Living (BADL) score
The tool assesses functional autonomy in simple everyday activities.
Time frame: From enrollment to the end of the assessment (1 day)
Instrumental Activities of Daily Living (IADL) score
The tool assesses functional autonomy in instrumental everyday activities.
Time frame: From enrollment to the end of the assessment (1 day)
Functional Activities Questionnaire (FAQ) score
The tool assesses functional autonomy in complex everyday activities
Time frame: From enrollment to the end of the assessment (1 day)
Neuropsychiatric Inventory Questionnaire (NPI-Q) score
The tool assesses Behavioral and Psychological Symptoms of Dementia (BPSD) , covering a wide range of neuropsychiatric symptoms.
Time frame: From enrollment to the end of the assessment (1 day)
Plan to share: Undecided
Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 24 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.